MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2026.111033

Медицинская библиотека · Urologic oncology · 2026

Association of denosumab treatment with survival and skeletal-related events in Asian men with mCRPC: A real-world observational study.

Kao Chien-Chang, Meng En, Cha Tai-Lung, Wu Chi-Tsung, Tsai Yi-Ta, Tsao Chih-Wei, Yang Ming-Hsin

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

To identify the effect of denosumab treatment on survival outcomes and skeletal related events (SREs) in Asian patients with castration-resistant prostate cancer (mCRPC).

MATERIALS AND

METHODS

The data of 268 patients with mCRPC were collected retrospectively between January 2019 and December 2023. Patient characteristics, SREs, treatment patterns, and AEs were analyzed. Descriptive statistics showed baseline characteristics, SRE rates, and denosumab use. Comparisons between groups were performed using independent t-tests and chi-squared analyses. PSA progression-free survival (PSA-PFS), SRE-free survival (SRE-FS), time to opiate use survival, and overall survival (OS) were calculated using the log-rank test and Kaplan-Meier method. A Cox proportional hazards regression model was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for multivariate and univariate analyses to identify the factors associated with SRE-FS, time to opioid use survival, PSA-PFS, and OS.

RESULTS

A total of 156 men underwent denosumab treatment. Denosumab significantly reduced SRE incidence (P = 0.0008). In unadjusted analyses, denosumab treatment was associated with prolonged SRE-FS (P < 0.001), delayed time to opioid use (P = 0.047), and improved OS (P = 0.047); however, PSA-PFS showed a borderline trend without statistical significance (P = 0.069). Notably, after adjusting for confounders, multivariate analysis demonstrated that denosumab treatment was an independent prognostic factor for superior SRE-FS, time to opioid use, OS, and PSA-PFS (P = 0.006).

CONCLUSION

In men with mCRPC, denosumab treatment was associated with a lower risk of SREs, longer time to opioid use, and longer time to first SRE occurrence. Furthermore, denosumab was associated with improved overall survival in this Asian cohort.

Для цитирования: Kao Chien-Chang, Meng En, Cha Tai-Lung, Wu Chi-Tsung, Tsai Yi-Ta, Tsao Chih-Wei, Yang Ming-Hsin. Association of denosumab treatment with survival and skeletal-related events in Asian men with mCRPC: A real-world observational study.. Urologic oncology. 2026. DOI: 10.1016/j.urolonc.2026.111033.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.